SCHEMBL6847730

SCHEMBL6847730

CCOc1ccc(S(=O)(=O)N(CC(=O)NC(C(N)=O)c2ccccc2)c2ccc(F)cc2)cc1.CCOc1ccc(S(=O)(=O)N(CC(=O)NC(Cc2c[nH]c3ccccc23)C(N)=O)c2ccc(F)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA9 Q16790 2/20 0.49
KEAP1 Q14145 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
POLB P06746 3/20 0.45
KCNA5 P22460 2/20 0.45
GAA P10253 1/20 0.45
HTT P42858 1/20 0.45
SCN9A Q15858 1/20 0.45
HCRTR1 O43613 1/20 0.44
HCRTR2 O43614 1/20 0.44
P2RY14 Q15391 1/20 0.44
ADAM17 P78536 2/20 0.44
TP53 P04637 2/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3365542 0.95 CA12 (0.53) CA12CA1CA9KEAP1MEN1
SCHEMBL3366682 0.89 KEAP1 (0.54) CA12CA1CA9KEAP1MEN1
SCHEMBL3369175 0.86 MEN1 (0.56) MEN1KMT2APOLBGAAHCRTR1
SCHEMBL3365718 0.79 KMT2A (0.66) MEN1KMT2APOLBGAAHCRTR1
SCHEMBL3364635 0.71 MEN1 (0.58) KEAP1MEN1KMT2APOLBGAA
SCHEMBL24024001 0.69 ECE1 (0.65) CA12CA1CA9MEN1KMT2A
SCHEMBL31238592 0.68 ECE1 (0.64) CA12CA1CA9MEN1KMT2A
SCHEMBL3364015 0.67 MAPT (0.58) KEAP1MEN1KMT2APOLBGAA
SCHEMBL3366747 0.67 MAPT (0.45) MEN1KMT2APOLBGAAHTT
SCHEMBL3366525 0.67 OXTR (0.73) MEN1KMT2APOLBGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives MERCK SERONO SA (CH) 2004-04-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives OXTR, AVPR2, OPRL1 CA12 3730/4885CA1 4063/4885CA9 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.